The Value of Targeting Complement Components in Asthma

Medicina (Kaunas). 2020 Aug 12;56(8):405. doi: 10.3390/medicina56080405.

Abstract

Asthma is an important respiratory illness. Though pharmacological and biological treatment is well established and is staged according to endotypes and their responses to treatment, novel avenues are being explored. Our focus is complement. In this viewpoint, we evaluate the approach to target complement in this complex hypersensitivity reaction that develops chronicity and has a personal-as well as a societal-cost.

Keywords: asthma; complement; treatment.

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Asthma / drug therapy*
  • Asthma / immunology*
  • Complement C3a / immunology*
  • Complement C5a / immunology*
  • Complement Inactivating Agents / therapeutic use*
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Complement Inactivating Agents
  • Complement C3a
  • Complement C5a
  • eculizumab